No Data
US Stock MarketDetailed Quotes
OPT Opthea
Watchlist
1.700
-0.042-2.41% Close 10/02 16:00 ET
1.750High1.700Low32.27KVolume
1.750Open1.742Pre Close54.96KTurnover0.06%Turnover RatioLossP/E (TTM)140.85MMarket Cap6.09052wk HighLossP/E (Static)82.85MShares1.67652wk Low-23.94P/B98.18MFloat Cap16.230Historical High--Dividend TTM57.75MShs Float1.676Historical Low--Div YieldTTM2.87%Amplitude1.702Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Opthea Company
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.
Revenue Breakdown
Business
Unit:USD
06/30/2023
Stock NameRevenueRatio
Biotechnology and healthcare industry108.41K100.00%
News
Opthea to Participate at the 2023 Euretina Congress
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT)), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal
Opthea Completes Retail Entitlement Offer; Shares Fall 3%
Opthea (ASX:OPT) completed the retail component of its 1-for-3.07 nonrenounceable entitlement offer. The retail entitlement offer raised AU$16.3 million, with eligible shareholders taking up about 8.1
Opthea's Options Suspended From Quotation on ASX; Shares Rise 3%
The options of Opthea (ASX:OPT), trading under the ticker OPTOA on the Australian Securities Exchange, will be suspended immediately from quotation on the index, the biopharmaceutical company said Fri
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--